Azitra (AZTR) Enterprise Value (2022 - 2026)
Azitra's (AZTR) quarterly Enterprise Value came in at -$10.1 million in Q1 2026, down 213.44% YoY from $8.9 million in Q1 2025, and down 386.01% on a QoQ basis from -$2.1 million in Q4 2025.
Azitra (AZTR) Enterprise Value (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Enterprise Value data on file, last reported at -$10.1 million in Q1 2026.
- Quarterly Enterprise Value fell 213.44% year-over-year to -$10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.1 million (down 213.44% YoY) and the FY2025 annual result came in at -$2.1 million, up 54.59% from the prior year.
- Enterprise Value eased to -$10.1 million in Q1 2026, from -$2.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$803082.0 in Q2 2024 to a low of -$10.1 million in Q1 2026.
- A 5-year average of -$3.8 million and a median of -$3.2 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2024 — Enterprise Value surged 87.23% — and 2026, when it sank 213.44%.
- Tracing AZTR's Enterprise Value over 5 years: stood at -$3.5 million in 2022, then jumped by 48.58% to -$1.8 million in 2023, then tumbled by 153.61% to -$4.6 million in 2024, then surged by 54.59% to -$2.1 million in 2025, then sank by 386.01% to -$10.1 million in 2026.
- The last three Enterprise Value figures came in at -$10.1 million (Q1 2026), -$2.1 million (Q4 2025), and -$1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | 2.12 Bn |
| 10 | Azitra | 2.68 Mn | 2.68 Mn | - | -6.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.73 Mn |
| Mar 31, 2026 | -10.05 Mn |
| Dec 31, 2025 | -2.07 Mn |
| Sep 30, 2025 | -1.40 Mn |
| Jun 30, 2025 | -1.05 Mn |
| Mar 31, 2025 | -3.21 Mn |
| Dec 31, 2024 | -4.55 Mn |
| Sep 30, 2024 | -7.26 Mn |
| Jun 30, 2024 | -803,082.00 |
| Mar 31, 2024 | -3.00 Mn |
| Dec 31, 2023 | -1.80 Mn |
| Sep 30, 2023 | -4.40 Mn |
| Jun 30, 2023 | -6.29 Mn |
| Dec 31, 2022 | -3.49 Mn |